Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors
CSET N° 2017/2523
Phase 2 other active
Quick answer
Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors for Pancreatic well differentiated neuroendocrine tumors (NET) is a Phase 2 program (other) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Pancreatic well differentiated neuroendocrine tumors (NET)
- Phase
- Phase 2
- Modality
- other
- Status
- active